Loading...
NPI 1073978946 · Richardson, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Trident Diagnostics Limited Liability Company is a clinical medical laboratory provider located in Richardson, Texas. This profile covers 1 Medicare and 33 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Trident Diagnostics Limited Liability Company |
| Address | 1840 N Greenville Ave Ste 178 |
| City | Richardson |
| State | TX |
| ZIP | 75081 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 20, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $14.9M |
| Medicaid | $66.7K |
TRIDENT DIAGNOSTICS’ Medicare billing is overwhelmingly driven by a single COVID-19 retail/self-test code: K1034 is reported with 1.3M claims, $12 avg paid/claim and $15.2M revenue, and the precomputed capture shows the top 3 Medicare codes account for 100.0% of this provider's total Medicare revenue. The K1034 description (provision of nonprescription self-administered, self-collected COVID-19 tests) points to a business model oriented toward distribution or provision of OTC/self-test kits rather than high-volume, in-house clinical laboratory processing.
Revenue concentration is extreme on the Medicare side: the provider lists $14.9M in total Medicare revenue while the top-3 Medicare codes are precomputed to account for 100.0% of that Medicare revenue, with K1034 alone listed as an outlier. The Medicare rank for K1034 is #32 of 30143 nationally (100th percentile; extreme outlier), indicating volumes for that code are far above typical national peers and drive nearly all Medicare receipts.
The provider’s payer mix is effectively Medicare-dominant by scale: lifetime Medicare revenue is $14.9M compared with lifetime Medicaid revenue of $66.7K. Medicaid is present but small by comparison, so changes in Medicare reimbursement or coding for COVID-related provisioning will disproportionately affect this entity’s topline.
Medicaid billing shows a different, more mixed clinical profile: the top Medicaid code is U0004 at $35.6K (55.2% of this provider's total Medicaid revenue) followed by U0005 ($3.4K) and K1034 ($2.6K), and the precomputed top-3 Medicaid codes account for 64.6% of Medicaid revenue. Beyond those COVID-related codes, the Medicaid claims list includes a broad set of routine lab tests and hormone assays (A1C, parathyroid hormone, testosterone panels, ferritin, etc.) at modest volumes and dollar amounts, suggesting TRIDENT also bills for conventional clinical laboratory services to Medicaid but at much lower scale.
Competitive standing differs sharply by payer and code: for Medicare K1034 the provider ranks #32 of 30143 (100th percentile; extreme outlier), which represents national-scale prominence for that single code. By contrast, Medicaid rankings for U0004 (#43 of 104, 59th percentile) and U0005 (#164 of 257, 36th percentile) are unimpressive to typical in-state volumes, though the provider’s Medicaid K1034 ranking (#9 of 77, 89th percentile) is comparatively strong in-state for that specific retail-test code.
The provider has an established NPI tenure (enumerated 2015-12-20 (~11 years ago)), indicating it is not a brand-new registrant; however, its recent revenue profile shows a pronounced shift toward high-volume COVID test provisioning under K1034. This tenure combined with a pandemic-era code concentration suggests operational activity ramped to meet pandemic testing demand rather than long-standing dominance across diverse clinical testing lines.
Payer reimbursement patterns are heterogeneous and likely influence product mix: Medicare lists K1034 with a $12 avg paid/claim while Medicaid shows K1034 at $1 avg paid/claim and U0004 at $54 avg paid/claim. Those per-claim payment differentials, together with the very large Medicare claim count for K1034 (1.3M), help explain why Medicare revenue dominates overall while Medicaid remains a much smaller revenue source despite billing for many different test types.
From a risk and strategic perspective, TRIDENT’s reliance on a single high-volume Medicare code creates concentration vulnerability: the provider’s Medicare revenue is dominated by K1034 (top-3 Medicare codes = 100.0% of Medicare revenue), whereas Medicaid receipts are smaller and more dispersed (top-3 Medicaid codes = 64.6% of Medicaid revenue). Analysts tracking network participation, policy changes to COVID-test coverage, or payer edits for K1034 should consider this provider high-impact for that code but otherwise a modest Medicaid clinical lab participant.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,263,140 | $10 | $15.2M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 6 | 2,490 | 450 | $10 | $117.8K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
33 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 660 | $50 | $35.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 240 | $10 | $3.4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2,640 | $1 | $2.6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 30 | $80 | $2.3K |
| 83970 | Parathyroid hormone test measures the level of PTH in the blood. This test is done to ascertain the level of calcium and evaluate the parathyroid function. | 60 | $40 | $2.1K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 40 | $60 | $2K |
| 82670 | The lab analyst measures the level of total estradiol, an estrogenic hormone, on a specimen such as blood using a method such as liquid chromatography–tandem mass spectrometry (LC–MS/MS) to evaluate… | 60 | $30 | $1.4K |
| 84402 | The lab analyst performs a test to measure free testosterone, typically in patient serum. | 60 | $20 | $1.3K |
| 84403 | The lab analyst performs a test to measure total testosterone, typically in patient serum. | 50 | $20 | $1.3K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 40 | $30 | $1.3K |
Showing 1–10 of 33
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
33 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 298 | 340 | 400 | $50 | $553.5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 43 | 100 | 470 | $50 | $319.1K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 114 | 150 | 170 | $30 | $302.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 164 | 260 | 640 | $20 | $137.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 298 | 350 | 510 | $30 | $114.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 694 | 730 | 1,270 | $10 | $84.8K |
| 84402 | The lab analyst performs a test to measure free testosterone, typically in patient serum. | 13 | 20 | 210 | $10 | $69.6K |
| 84403 | The lab analyst performs a test to measure total testosterone, typically in patient serum. | 41 | 70 | 140 | $10 | $67.2K |
| 82670 | The lab analyst measures the level of total estradiol, an estrogenic hormone, on a specimen such as blood using a method such as liquid chromatography–tandem mass spectrometry (LC–MS/MS) to evaluate… | 32 | 40 | 210 | $10 | $57.2K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 444 | 480 | 400 | $10 | $43.8K |
Showing 1–10 of 33
Other providers in the same ZIP code as Trident Diagnostics Limited Liability Company, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Caregivers Home Health Tx Inc | TX | Home Health Agency | $0 | $478M |
| Apple Homecare Medical Supply LLC | TX | Durable Medical Equipment & Medical Supplies | $0 | $123.3M |
| Hope Pediatrics LLC | TX | Home Health Agency | $0 | $77.9M |
| Abc Home Medical Supply, Inc. | TX | Durable Medical Equipment & Medical Supplies | $0 | $22.8M |
| Rfa Medical Solutions LLC | TX | Clinical Medical Laboratory | $6.4M | $0 |
| Cabot Lab LLC | TX | Clinical Medical Laboratory | $278.1K | $1.2M |
| Curie Dx Laboratory LLC | TX | Clinical Medical Laboratory | $664.4K | $2.8K |
| Shahida Rafiq | TX | Family Medicine Physician | $232.7K | $0 |
| Pearl Ezegrim | TX | Psychiatric/Mental Health Nurse Practitioner | $110.1K | $40 |
| Francis Lister | TX | Optometrist | $23.8K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.